Ap­n­imed, a late-stage sleep ap­nea biotech, eyes IPO in the sec­ond half

Ap­n­imed, which has a nov­el sleep ap­nea drug in Phase III, is con­sid­er­ing a po­ten­tial IPO in the sec­ond half of this year even as biotech en­tries to Wall Street have start­ed to slow.

The com­pa­ny’s cur­rent­ly talk­ing to bankers, CEO Lar­ry Miller told End­points News in an in­ter­view on Tues­day, and is well po­si­tioned to take ad­van­tage of in­vestor de­mands af­ter one more pri­vate fi­nanc­ing ex­pect­ed in the first half of this year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER